PLRX vs. BCAX, VERV, MNMD, DNTH, AVXL, OPT, SANA, LENZ, QURE, and RLAY
Should you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Bicara Therapeutics (BCAX), Verve Therapeutics (VERV), Mind Medicine (MindMed) (MNMD), Dianthus Therapeutics (DNTH), Anavex Life Sciences (AVXL), Opthea (OPT), Sana Biotechnology (SANA), LENZ Therapeutics (LENZ), uniQure (QURE), and Relay Therapeutics (RLAY). These companies are all part of the "pharmaceutical products" industry.
Pliant Therapeutics vs.
Pliant Therapeutics (NASDAQ:PLRX) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, community ranking, media sentiment, earnings, risk and institutional ownership.
In the previous week, Pliant Therapeutics had 2 more articles in the media than Bicara Therapeutics. MarketBeat recorded 5 mentions for Pliant Therapeutics and 3 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.58 beat Pliant Therapeutics' score of 0.08 indicating that Bicara Therapeutics is being referred to more favorably in the news media.
Bicara Therapeutics' return on equity of 0.00% beat Pliant Therapeutics' return on equity.
Pliant Therapeutics received 65 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Bicara Therapeutics an outperform vote while only 69.72% of users gave Pliant Therapeutics an outperform vote.
Bicara Therapeutics has lower revenue, but higher earnings than Pliant Therapeutics.
97.3% of Pliant Therapeutics shares are owned by institutional investors. 6.4% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Pliant Therapeutics presently has a consensus target price of $17.75, suggesting a potential upside of 476.30%. Bicara Therapeutics has a consensus target price of $41.20, suggesting a potential upside of 216.92%. Given Pliant Therapeutics' higher possible upside, equities analysts clearly believe Pliant Therapeutics is more favorable than Bicara Therapeutics.
Summary
Pliant Therapeutics and Bicara Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.
Get Pliant Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pliant Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:PLRX) was last updated on 2/22/2025 by MarketBeat.com Staff
